Clinical Research at Xenoscience
Enrolling in a clinical research trial can be a rewarding experience. In our view at Xenoscience and 21st Century Neurology, participation is always optional (our doctors are willing to take care of patients using conventional therapy) and voluntary (you can enter and then decide to stop participating at any time without penalty). Some trials below have a placebo, which is a 'sugar pill' or a treatment that has no effect so the trial can be unbiased and prove that a drug works, and many of those trials also have an Open Label Extension during which participants will get the real experimental drug, provided they complete the first part, often called the Double-Blind Phase.
Please see the information at the FDA's website for more on participating in clinical trials.
Alzheimer's Disease
Alzheimer's disease trials offer medication to improve cognition and thinking and in some cases test medicine which may delay the progression of the condition. If you or someone you know is interested in enrolling, please use the form below.
| Type of Drug | Phase | Stage | Add-On | Placebo | Duration | Open Label Extension |
|---|---|---|---|---|---|---|
| H3 modulator | III | Any | Aricept | Yes | 24 weeks | No |
Parkinson's Disease
Parkinson's disease trials offer medication to improve mobility and in some cases test medicine which may delay the progression of the condition. If you or someone you know is interested in enrolling, please use the form below.
| Type of Drug | Phase | Stage | Add-On | Placebo | Duration | Open Label Extension |
|---|---|---|---|---|---|---|
| Anti-hypotensive | III | Any | Standard Therapy | Yes | 12 weeks | Yes |
Seizure Disorder and Epilepsy
Epilepsy or Seizure Disorder is the tendency to have recurrent seizures. These trials offer medication or devices to reduce seizure frequency. In some cases they may also test an approach to delay the progression of the condition. If you or someone you know is interested in enrolling, please use the form below. For ethical reasons, trials which involve placebo are always Add-On, where a patient may receive a placebo (sugar pill) he or she will still be taking at least one anti-seizure medication.
| Type of Seizures | Type of Drug | Phase | Add-On | VNS Allowed | Placebo | Duration | Open Label Extension |
|---|---|---|---|---|---|---|---|
| Partial Seizures | Slow sodium-channel modulator | III | No | No | No | 30 weeks | Yes |
| Partial Seizures | Fast sodium-channel blocker | III | Yes | Yes | 33% | 22 weeks | 1 year |
| Partial Seizures | Fast sodium-channel blocker | III | No | Yes | No | 18 weeks | 1 year |
| Partial Seizures | Once daily fast sodium-channel blocker | III | Yes | Yes | 33% | 35 weeks | Yes |
| Partial Seizures | AMPA receptor blocker | III | Yes | Yes | 33% | 25 weeks | Yes |
Migraine
Migraine trials offer medication to reduce frequency of attacks. If you or someone you know is interested in enrolling, please use the form
| Type of Drug | Phase | Add-On | Placebo | Duration | Open Label Extension |
|---|---|---|---|---|---|
| Novel Agent | II | No | 50% | 6 months | No |
Multiple Sclerosis
Multiple sclerosis trials offer medication to reduce attack frequency. In some cases they may also test an approach to delay the progression of the condition. Others address symptoms like pain or spasticity (stiff muscles) in MS. If you or someone you know is interested in enrolling, please use the form below.
| Subtype of MS | Type of Drug | Phase | Add-On | Placebo | Duration | Open Label Extension |
|---|---|---|---|---|---|---|
| Relapsing-Remitting | Interferon plus Oral Immunomodulator | III | Yes | 33% | 24 months | Yes |
| First Clinical Episode Suggestive of MS | Oral Immunomodulator | III | Yes | 33% | 24-30 months | Yes |
| Relapsing-Remitting | Interferon vs. Intravenous Immunomodulator | III | No | 0% (1:1) | 24 months | Yes |
| Spasticity in any type of MS | Long-acting Antispasmodic | III | No | 25% | 12 weeks | Yes |
Response Form
If you or a loved one is interested in participating in one of our trials, please contact us at (855) 829-8899 or use the form below. One of our skilled Clinical Research Coordinators will contact you as soon as possible. Thank you for your interest in our research!
